Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

VBI Vaccines is recalling PreHevbrio and shutting down operations amid bankruptcy. Despite FDA approval in 2021, the ...

New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, ...

Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano (pictured, above) as chief business ...

Australia’s CSL Behring (ASX: CSL) plans to shut down its Californian R&D facility focused on cell and gene therapies by ...

Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates.

AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

UK clinical-stage gene specialist Silence Therapeutics (Nasdaq: SLN) yesterday presented end-of-treatment data from its Phase ...

Swiss cancer giant Novartis (NOVN: VX) has entered into an exclusive worldwide licensing and collaboration deal with Ratio ...